Last $4.26 USD
Change Today +0.16 / 3.90%
Volume 3.0M
FOLD On Other Exchanges
As of 4:00 PM 07/24/14 All times are local (Market data is delayed by at least 15 minutes).

amicus therapeutics inc (FOLD) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/24/14 - $4.56
52 Week Low
04/16/14 - $1.77
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

amicus therapeutics inc (FOLD) Related Bloomberg News

View More Bloomberg News

amicus therapeutics inc (FOLD) Related Businessweek News

No Related Businessweek News Found

amicus therapeutics inc (FOLD) Details

Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases. It develops enzyme replacement therapies (ERTs) for lysosomal storage disorders (LSDs), including Fabry disease, Pompe disease, and Mucopolysaccharoidosis Type I (MPS I). The company also develops novel small molecules as monotherapy treatments for Fabry disease and Parkinson's disease. Its chaperone-advanced replacement therapy program is used to develop next-generation ERTs by co-formulating therapeutic enzymes with proprietary pharmacological chaperones. The company’s lead programs include the small molecule pharmacological chaperones, migalastat HCl as a monotherapy that is in Phase III global registration studies for Fabry patients with genetic mutations; and AT2220 (duvoglustat HCl), which has completed Phase II safety used for the treatment of Pompe disease. Its products also comprise AT-B200, a proprietary recombinant human acid-alpha glucosidase that is in late preclinical development for Pompe disease; and AT3375 for treating Gaucher disease. The company has strategic collaboration with GlaxoSmithKline PLC to develop and commercialize migalastat HCl. Amicus Therapeutics, Inc. was founded in 2002 and is based in Cranbury, New Jersey.

92 Employees
Last Reported Date: 03/3/14
Founded in 2002

amicus therapeutics inc (FOLD) Top Compensated Officers

Chairman and Chief Executive officer
Total Annual Compensation: $824.1K
Chief Financial Officer and Secretary
Total Annual Compensation: $445.1K
Chief Operating Officer
Total Annual Compensation: $475.0K
Principal Accounting Officer, Vice President ...
Total Annual Compensation: $247.4K
Compensation as of Fiscal Year 2013.

amicus therapeutics inc (FOLD) Key Developments

Amicus Therapeutics Provides Updates and Final Analysis Plan for Phase 3 Fabry Monotherapy Study 012

Amicus Therapeutics provided updates and detailed the statistical analysis plan for its second Phase 3 study (Study 012) of the oral small molecule pharmacological chaperone migalastat HCl ("migalastat") monotherapy for Fabry patients with amenable mutations. The 18-month primary treatment period is now complete and top-line data from Study 012 are expected in the third quarter of 2014. If successful, Study 012 will trigger the process for European regulatory approval of migalastat as a monotherapy for Fabry patients with amenable mutations. Study 012 is the first clinical study to compare oral migalastat to standard-of-care enzyme replacement therapies (ERTs) for Fabry disease (Fabrazyme(R) and Replagal(R)). The primary outcome measure is renal function at 18 months. This open-label registration study enrolled 60 patients (26 males and 34 females) with Fabry disease with amenable mutations who had been treated with ERT for a minimum of 12 months prior to study entry. These patients were randomized 1.5:1 to switch to migalastat (36 patients) or remain on ERT (24 patients) for the primary 18-month treatment period, after which they were eligible to receive migalastat in a 12-month extension phase. Among the 60 patients enrolled, 56 (34 in the migalastat group and 22 in the ERT group) had amenable mutations in a GLP-validated human embryonic kidney (HEK) cell-based in vitro assay ('GLP HEK amenable'). Study 012 Patient Disposition results were, following randomization, 34 of 36 patients who switched to migalastat and 18 of 24 patients who continued with ERT completed the primary 18-month treatment period. Among patients completing the 18-month primary treatment period, 32 out of 34 in the migalastat group and 16 out of 18 in the ERT group had GLP HEK amenable mutations. 97% of patients with GLP HEK amenable mutations in the migalastat group (31 out of 32) elected to continue to receive migalastat in the 12-month treatment extension. 94% of patients with GLP HEK amenable mutations in the ERT group (15 out of 16) elected to switch from ERT to migalastat for the 12-month treatment extension. Study 012 Statistical Analysis Plan was taking into account scientific advice from European regulatory authorities, the pre-specified co-primary outcome measures of efficacy in Study 012 are the descriptive assessments of comparability of the mean annualized change in measured (iohexol) glomerular filtration rate (mGFR) and estimated GFR (eGFR) for migalastat and ERT. Both mGFR and eGFR are considered important measures of renal function. Success on mGFR and eGFR will be measured in two ways, a 50% overlap in the confidence intervals between the migalastat and ERT treatment groups; and Whether the mean annualized changes for patients receiving migalastat are within 2.2 mL/min/1.73 m2/yr of patients receiving ERT. Amicus has pre-specified that these renal function outcomes will be analyzed in patients with GLP HEK amenable mutations. Discussions with European regulators have centered on the entirety of the data to come from Study 012, considering the relatively low number of study participants due to the orphan nature of Fabry disease. In addition, in Europe the benefit/risk assessment is expected to be based on the overall data from this study and results from the entire clinical development program.

Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from Russell 2000 Index

Amicus Therapeutics, Inc. will be removed from the Russell 2000 Index.

Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from Russell 3000 Index

Amicus Therapeutics, Inc. will be removed from the Russell 3000 Index.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FOLD:US $4.26 USD +0.16

FOLD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for FOLD.
View Industry Companies

Industry Analysis


Industry Average

Valuation FOLD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 322.2x
Price/Book 8.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 217.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMICUS THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at